Emerge Diagnostics Secures $3 Million In Financing To Fuel Growth And Innovation
Soft tissue diagnostic company to aggressively accelerate sales, marketing and execution of breakthrough functional EMG technology
CARLSBAD, Calif., Feb. 2, 2015 /PRNewswire/ -- Emerge Diagnostics, the leader in functional EMG technology for the diagnosis and treatment of soft tissue injuries, announced today a $3 million financing to meet the demand for its Electrodiagnostic Functional Assessment (EFA), test and EFA Soft Tissue Management Program (EFA-STM).
"Emerge's functional EMG technology is a game-changing diagnostic evaluation that can objectively determine pre-injury condition of a soft tissue and whether there is a change in condition after a reported injury," said Robert Thompson, CEO of Emerge Diagnostics. "With new customers adopting the technology every month, and with the support of our investors, we can continue to expand our sales force and clinic network to meet the growing demand from employers nationwide."
The EFA test, an FDA Class II medical device, enables employers and occupational health clinics to objectively diagnose and identify the location, extent, nature and age of soft tissue injuries of the back, neck, shoulder, and extremities, including repetitive strain injuries. The test determines the injured muscle group as well as compliance, malingering and pain.
The EFA-STM Program measures current and new employees before and after workplace injuries to assist in determining if an injury arose out of the course and scope of employment. It objectively determines pre-injury status and whether there is a change in condition after the reported injury. These objective findings can prevent costly misdiagnoses, unnecessary or inappropriate surgeries, prolonged treatment periods, and fraudulent claims.
About Emerge Diagnostics
Headquartered in San Diego, Emerge Diagnostics is delivering a new way to determine the location and age of soft tissue injuries. The Company's technology provides the most comprehensive and actionable pre- and post-injury test to determine whether an injury actually arose in the workplace. Emerge Diagnostics works with employers, occupational health clinics and insurance carriers/TPAs to create better patient outcomes and reduced costs. Emerge is leading the way with technological development and ongoing innovation to improve workplace injury outcomes and return-to-work times. For more information, visit emergedx.com.